Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

Summary by Joplin Globe
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 15, 2026-

2 Articles

Joplin GlobeJoplin Globe
Center

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 15, 2026-

Read Full Article
cancernetwork.comcancernetwork.com

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Data from the phase 3 IMvigor011 trial support the approval of adjuvant atezolizumab in this ctDNA MRD-positive MIBC population.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Joplin Globe broke the news on Friday, May 15, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

United States icon

United States

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal